Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Working Capital Changes: 2009-2024

Historic Other Working Capital Changes for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to -$2.2 million.

  • Ironwood Pharmaceuticals' Other Working Capital Changes fell 68.91% to -$603,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year decrease of 55.89%. This contributed to the annual value of -$2.2 million for FY2024, which is 48.44% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Other Working Capital Changes stood at -$2.2 million for FY2024, which was up 48.44% from -$4.2 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Other Working Capital Changes ranged from a high of -$1.5 million in FY2020 and a low of -$4.2 million during FY2023.
  • In the last 3 years, Ironwood Pharmaceuticals' Other Working Capital Changes had a median value of -$3.2 million in 2022 and averaged -$3.2 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Other Working Capital Changes soared by 87.42% in 2020 and then slumped by 75.69% in 2022.
  • Over the past 5 years, Ironwood Pharmaceuticals' Other Working Capital Changes (Yearly) stood at -$1.5 million in 2020, then dropped by 21.12% to -$1.8 million in 2021, then slumped by 75.69% to -$3.2 million in 2022, then slumped by 30.89% to -$4.2 million in 2023, then soared by 48.44% to -$2.2 million in 2024.